MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024
December 11, 2023
NEW YORK, NY, December 11, 2023 – The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial